NCT06326372

Brief Summary

Oxygen therapy is the most common treatment modality for patients with hypoxemia, but target values for normoxemia are not clearly defined. Therefore, iatrogenic hyperoxemia is a very common situation. Even though there are many side effects reported related to hyperoxemia and hyperoxemia is shown to be related to worse outcome than expected; clinicians still observe hyperoxemia frequently. Oxygen reserve index (ORi™) (Masimo Corp., Irvine, USA) can guide clinicians in detection of hyperoxia. ORi is a parameter which can evaluate partial pressure of oxygen (PaO2) rating from 0 to 1. There are growing evidences in ORi that it might be helpful to reduce hyperoxia in general anesthesia. Continuous ORi monitoring can be used for detecting and preventing hyperoxia. The ability to perform FiO2 titration with ORi may be an appropriate monitoring management to prevent the harmful effects of hyperoxia.In this study, in patients who underwent major abdominal surgery; It was aimed to investigate the effectiveness of ORi-guided FiO2 titration in preventing hyperoxia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
114

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2023

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

March 16, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 22, 2024

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 5, 2024

Completed
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 7, 2024

Completed
Last Updated

July 9, 2024

Status Verified

March 1, 2024

Enrollment Period

9 months

First QC Date

March 16, 2024

Last Update Submit

July 7, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Correlation of FiO2 and ORi value

    Correlation of FiO2 value and ORi value. FiO2 adjusted until ORi reaches to zero and %95\<oxygen saturation≤%98

    Until the surgery is over

  • Correlation of ORi and Delirium

    Correlation of ORİ and SpO2 values with delirium measured by CAM and CAM-ICU

    Up to 48 hours

Secondary Outcomes (1)

  • Correlation of FiO2 and delirium

    first 10 th minutes after entubation and every 10 minutes until surgery is over

Study Arms (2)

Control group

In the control group, observation will be conducted solely by another anesthesia doctor or assistant participating in the study, and the data will be recorded blindly without being reported to the anesthesia doctor responsible for the surgery. The oxygen therapy administered by the anesthesia doctor in charge and the FiO2 values will be recorded independently and blindly, based solely on the clinician's own assessment, rather than according to the information obtained from ORi. Subsequently, for two days following the surgery, evaluations will be conducted twice daily at the same hours for ward patients using CAM, and for ICU patients using CAM-ICU. If delirium is detected, delirium subtyping will be performed using the Richmond Agitation-Sedation Scale (RASS).

Procedure: control

ORi+SpO2 group

In the SpO2+ORi group; It is aimed to maintain SpO2 between %95 and %98, and ORi at 0.00. Data will be recorded every 10 minutes. After extubation, patients will first be evaluated in the postoperative recovery room. Subsequently, for two days following the surgery, evaluations will be conducted twice daily at the same hours for ward patients using CAM, and for ICU patients using CAM-ICU. If delirium is detected, delirium subtyping will be performed using the Richmond Agitation-Sedation Scale (RASS).

Procedure: ORi+SpO2

Interventions

controlPROCEDURE

Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation

Control group
ORi+SpO2PROCEDURE

Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00. FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg

ORi+SpO2 group

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients aged 65 and older. Geriatric patients

You may qualify if:

  • Patients aged 65 and older
  • Patients expected to have surgery lasting more than 2 hours
  • Patients with ASA (American Society of Anesthesiologists) classification 1-2-3-4
  • Patients planned to have at least 2 days of postoperative hospitalization

You may not qualify if:

  • Patients with preoperative central nervous system disorders or dementia
  • Patients with MMSE (Mini-Mental State Examination) scores of 23 or below
  • Patients unable to communicate
  • Emergency surgeries
  • Patients who refuse to participate in the study
  • Patients using high-dose vasopressors
  • Patients with peripheral hypoperfusion
  • Hemodynamically unstable patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aykut Saritaş

Izmir, 35640, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Hyperoxia

Condition Hierarchy (Ancestors)

Signs and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
associated professor

Study Record Dates

First Submitted

March 16, 2024

First Posted

March 22, 2024

Study Start

October 1, 2023

Primary Completion

July 5, 2024

Study Completion

July 7, 2024

Last Updated

July 9, 2024

Record last verified: 2024-03

Locations